TNGX: רווח נקי למניה (EPS TTM) Tango Pharma

Tango Therapeutics (TNGX) is competing for leadership in cancer immunotherapy, a field where the risk of development obsolescence is extremely high. The venture model of Tango Therapeutics (TNGX) involves massive expenditures on genomics in pursuit of future superprofits from patents. Alliances with pharma behemoths are driving growth. The net income per share over the last 12 months on the GURU.Markets system summary chart demonstrates volatility, where -1.37 is recorded as the baseline value.

This indicator measures overall business efficiency by allocating total annual net income per common share to assess the actual return on equity. Analyzing annual net income per share allows for an evaluation of the financial stability of Tango Therapeutics (TNGX), where cost optimization through the outsourcing of clinical trials directly impacts the company's final margins and capitalization rates.